XML 54 R42.htm IDEA: XBRL DOCUMENT v3.23.4
SCHEDULE OF DISCONTINUED OPERATIONS (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenue $ 124,238 $ 344,508 $ 761,306 $ 925,507
Cost of sales 127,671 314,945 705,206 1,019,470
Gross profit (3,433) 29,563 56,100 (93,963)
Operating expenses        
Wage and salary expense 108,772 87,691 456,297 235,758
Professional fees 18,079 12,565 23,371 50,534
Accounting and legal expense 2,648 604 70,773 604
Technology expense 6,408 60,009 30,075 151,558
General and administrative 4,391 58,862 36,592 92,579
Total operating expense 140,298 219,731 617,108 531,033
Operating loss from discontinued operations (143,731) (190,168) (561,008) (624,996)
Other income (expense)        
Gain (loss) on disposal of assets (3,209,776) 1,900 (3,562,020) 1,900
Total other income (expense) (3,209,776) 1,900 (3,562,020) 1,900
Loss from discontinued operations $ (3,353,507) $ (188,268) $ (4,123,028) $ (623,096)
Loss per common share from discontinued operations        
Basic $ (4.35) $ (0.34) $ (5.82) $ (1.14)
Diluted $ (1.42) $ (0.34) $ (1.79) $ (1.14)
SOSRx [Member]        
Revenue $ 3,368 $ 20,424
Cost of sales
Gross profit 3,368 20,424
Operating expenses        
Wage and salary expense 17,689 54,939
Professional fees
Accounting and legal expense
Technology expense 23,000 53,910
General and administrative 29,907 33,873
Total operating expense 70,596 142,722
Operating loss from discontinued operations (67,228) (122,298)
Other income (expense)        
Gain (loss) on disposal of assets (352,244)
Total other income (expense) (352,244)
Loss from discontinued operations $ (67,228) $ (352,244) $ (122,298)
Loss per common share from discontinued operations        
Basic $ (0.12) $ (0.50) $ (0.22)
Diluted $ (0.12) $ (0.15) $ (0.22)
Alliance Pharma Solution [Member]        
Revenue
Cost of sales
Gross profit
Operating expenses        
Wage and salary expense
Professional fees 10,471 3,125 44,962
Accounting and legal expense 1,948 104 7,773 104
Technology expense 4,177 31,564 20,611 83,659
General and administrative 134 3,527 3,762 10,761
Total operating expense 6,259 45,666 35,271 139,486
Operating loss from discontinued operations (6,259) (45,666) (35,271) (139,486)
Other income (expense)        
Gain (loss) on disposal of assets (1,783,209) 1,900 (1,783,209) 1,900
Total other income (expense) (1,783,209) 1,900 (1,783,209) 1,900
Loss from discontinued operations $ (1,789,468) $ (43,766) $ (1,818,480) $ (137,586)
Loss per common share from discontinued operations        
Basic $ (2.32) $ (0.08) $ (2.57) $ (0.25)
Diluted $ (0.76) $ (0.08) $ (0.79) $ (0.25)
Community Speciality Pharmacy [Member]        
Revenue $ 124,238 $ 341,140 $ 761,306 $ 905,083
Cost of sales 127,671 314,945 705,206 1,019,470
Gross profit (3,433) 26,195 56,100 (114,387)
Operating expenses        
Wage and salary expense 108,772 70,002 456,297 180,819
Professional fees 18,079 2,094 20,246 5,572
Accounting and legal expense 700 500 63,000 500
Technology expense 2,231 5,445 9,464 13,989
General and administrative 4,257 25,428 32,830 47,945
Total operating expense 134,039 103,469 581,837 248,825
Operating loss from discontinued operations (137,472) (77,274) (525,737) (363,212)
Other income (expense)        
Gain (loss) on disposal of assets (1,426,567) (1,426,567)
Total other income (expense) (1,426,567) (1,426,567)
Loss from discontinued operations $ (1,564,039) $ (77,274) $ (1,952,304) $ (363,212)
Loss per common share from discontinued operations        
Basic $ (2.03) $ (0.14) $ (2.76) $ (0.66)
Diluted $ (0.66) $ (0.14) $ (0.85) $ (0.66)